一次情報の記録
決定級FDA添付文書の更新
Abbott Receives FDA Approval for Libre Duo Dual Glucose-Ketone Sensor
Abbott announced FDA approval of Libre Duo, the first dual glucose-ketone biowearable sensor. The device provides real-time visibility into both glucose and ketone levels to help detect rising ketones that can lead to diabetic ketoacidosis.
主要事実
出典の抜粋
EX-99.1 2 abt-2026q3xexhibitx991.htm EX-99.1 Document Exhibit 99.1 News Release Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance – Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent – Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 – Expands portfolio with key new product approvals ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for the third quarter ended Sept. 30, 2026. • Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis. • Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items. • Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 pe